A Hexavalent Human Rotavirus-Bovine Rotavirus (UK) Reassortant Vaccine Designed for Use in Developing Countries and Delivered in a Schedule with the Potential to Eliminate the Risk of Intussusception

A. Z. Kapikian, Lone Simonsen, Timo Vesikari, Yasutaka Hoshino, David M. Morens, Robert M. Chanock, John R. La Montagne, Brian R. Murphy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Resumé

There is an urgent need for a rotavirus vaccine, because up to 592,000 infants and young children < 5 years old die each year from rotavirus diarrhea, predominantly in the developing countries. We have developed a tetravalent human-bovine rotavirus (UK) reassortant vaccine with VP7 (G) specificity for serotypes 1, 2, 3, and 4, which has been shown to be safe, immunogenic, and effective in preventing severe rotavirus diarrhea. However, because of the emergence of VP7 (G) serotype 9 as an epidemiologically important serotype and the importance of VP7 (G) serotype 8 in focal areas, we are planning to add human-bovine (UK) reassortants with G8 and G9 specificity to the tetravalent vaccine, thereby formulating a "designed" hexavalent vaccine for universal use. In addition, we propose that the vaccine be administered orally in a 2-dose schedule, with the first dose given at 0-4 weeks of age and the second dose given at 4-8 weeks of age, when infants are relatively refractory to developing intussusception, thereby avoiding the age period when naturally occurring intussusception is most prevalent (i.e., ages 3-4 months through age 9 months). In this way, there may be the potential to eliminate or at least significantly decrease the risk of intussusception associated with rotavirus vaccination.
OriginalsprogEngelsk
TidsskriftJournal of Infectious Diseases
Vol/bind192
Udgave nummerSupplement 1
Antal sider8
ISSN0022-1899
StatusUdgivet - 2005
Udgivet eksterntJa

Citer dette

Kapikian, A. Z. ; Simonsen, Lone ; Vesikari, Timo ; Hoshino, Yasutaka ; Morens, David M. ; Chanock, Robert M. ; La Montagne, John R. ; Murphy, Brian R. / A Hexavalent Human Rotavirus-Bovine Rotavirus (UK) Reassortant Vaccine Designed for Use in Developing Countries and Delivered in a Schedule with the Potential to Eliminate the Risk of Intussusception. I: Journal of Infectious Diseases. 2005 ; Bind 192, Nr. Supplement 1.
@article{9ac8e4ea6a9248a6997cf7c2c7520c30,
title = "A Hexavalent Human Rotavirus-Bovine Rotavirus (UK) Reassortant Vaccine Designed for Use in Developing Countries and Delivered in a Schedule with the Potential to Eliminate the Risk of Intussusception",
abstract = "There is an urgent need for a rotavirus vaccine, because up to 592,000 infants and young children < 5 years old die each year from rotavirus diarrhea, predominantly in the developing countries. We have developed a tetravalent human-bovine rotavirus (UK) reassortant vaccine with VP7 (G) specificity for serotypes 1, 2, 3, and 4, which has been shown to be safe, immunogenic, and effective in preventing severe rotavirus diarrhea. However, because of the emergence of VP7 (G) serotype 9 as an epidemiologically important serotype and the importance of VP7 (G) serotype 8 in focal areas, we are planning to add human-bovine (UK) reassortants with G8 and G9 specificity to the tetravalent vaccine, thereby formulating a {"}designed{"} hexavalent vaccine for universal use. In addition, we propose that the vaccine be administered orally in a 2-dose schedule, with the first dose given at 0-4 weeks of age and the second dose given at 4-8 weeks of age, when infants are relatively refractory to developing intussusception, thereby avoiding the age period when naturally occurring intussusception is most prevalent (i.e., ages 3-4 months through age 9 months). In this way, there may be the potential to eliminate or at least significantly decrease the risk of intussusception associated with rotavirus vaccination.",
author = "Kapikian, {A. Z.} and Lone Simonsen and Timo Vesikari and Yasutaka Hoshino and Morens, {David M.} and Chanock, {Robert M.} and {La Montagne}, {John R.} and Murphy, {Brian R.}",
year = "2005",
language = "English",
volume = "192",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "Supplement 1",

}

A Hexavalent Human Rotavirus-Bovine Rotavirus (UK) Reassortant Vaccine Designed for Use in Developing Countries and Delivered in a Schedule with the Potential to Eliminate the Risk of Intussusception. / Kapikian, A. Z.; Simonsen, Lone; Vesikari, Timo; Hoshino, Yasutaka; Morens, David M.; Chanock, Robert M.; La Montagne, John R.; Murphy, Brian R.

I: Journal of Infectious Diseases, Bind 192, Nr. Supplement 1, 2005.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

TY - JOUR

T1 - A Hexavalent Human Rotavirus-Bovine Rotavirus (UK) Reassortant Vaccine Designed for Use in Developing Countries and Delivered in a Schedule with the Potential to Eliminate the Risk of Intussusception

AU - Kapikian, A. Z.

AU - Simonsen, Lone

AU - Vesikari, Timo

AU - Hoshino, Yasutaka

AU - Morens, David M.

AU - Chanock, Robert M.

AU - La Montagne, John R.

AU - Murphy, Brian R.

PY - 2005

Y1 - 2005

N2 - There is an urgent need for a rotavirus vaccine, because up to 592,000 infants and young children < 5 years old die each year from rotavirus diarrhea, predominantly in the developing countries. We have developed a tetravalent human-bovine rotavirus (UK) reassortant vaccine with VP7 (G) specificity for serotypes 1, 2, 3, and 4, which has been shown to be safe, immunogenic, and effective in preventing severe rotavirus diarrhea. However, because of the emergence of VP7 (G) serotype 9 as an epidemiologically important serotype and the importance of VP7 (G) serotype 8 in focal areas, we are planning to add human-bovine (UK) reassortants with G8 and G9 specificity to the tetravalent vaccine, thereby formulating a "designed" hexavalent vaccine for universal use. In addition, we propose that the vaccine be administered orally in a 2-dose schedule, with the first dose given at 0-4 weeks of age and the second dose given at 4-8 weeks of age, when infants are relatively refractory to developing intussusception, thereby avoiding the age period when naturally occurring intussusception is most prevalent (i.e., ages 3-4 months through age 9 months). In this way, there may be the potential to eliminate or at least significantly decrease the risk of intussusception associated with rotavirus vaccination.

AB - There is an urgent need for a rotavirus vaccine, because up to 592,000 infants and young children < 5 years old die each year from rotavirus diarrhea, predominantly in the developing countries. We have developed a tetravalent human-bovine rotavirus (UK) reassortant vaccine with VP7 (G) specificity for serotypes 1, 2, 3, and 4, which has been shown to be safe, immunogenic, and effective in preventing severe rotavirus diarrhea. However, because of the emergence of VP7 (G) serotype 9 as an epidemiologically important serotype and the importance of VP7 (G) serotype 8 in focal areas, we are planning to add human-bovine (UK) reassortants with G8 and G9 specificity to the tetravalent vaccine, thereby formulating a "designed" hexavalent vaccine for universal use. In addition, we propose that the vaccine be administered orally in a 2-dose schedule, with the first dose given at 0-4 weeks of age and the second dose given at 4-8 weeks of age, when infants are relatively refractory to developing intussusception, thereby avoiding the age period when naturally occurring intussusception is most prevalent (i.e., ages 3-4 months through age 9 months). In this way, there may be the potential to eliminate or at least significantly decrease the risk of intussusception associated with rotavirus vaccination.

M3 - Journal article

VL - 192

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - Supplement 1

ER -